Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

James M. Rossetti, Rushir Choksi, Purvi Suthar, Phoebe Davis, Anupama Vasudevan, Poras Dave, Varun Vaidya, Brandon Wang, Harvey I. Katzen

Blood (2023) 142 (Supplement 1): 5186.

https://doi.org/10.1182/blood-2023-179402

Published: 2023

Journal Articles

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

James M. Rossetti, Rushir Choksi, Anupama Vasudevan, Simon Blanc, Dawn Brenneman, Brandon Wang, Peter McMahon, Jason Beal, Teraneh Z. Jhaveri, Mellissa Williamson, Cosmina Hogea

Blood (2023) 142 (Supplement 1): 5101.

https://doi.org/10.1182/blood-2023-186836

Published: 2023

Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood (2023) 142 (Supplement 1): 747.

https://doi.org/10.1182/blood-2023-179329

Published: 2023

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Blood (2022) 140 (Supplement 1): 1784–1787.

https://doi.org/10.1182/blood-2022-159047

Published: 2022

Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis

Blood (2022) 140 (Supplement 1): 6145–6146.

https://doi.org/10.1182/blood-2022-156468

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Blood (2022) 140 (Supplement 1): 9717–9720.

https://doi.org/10.1182/blood-2022-167122

Published: 2022

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

Blood (2021) 138 (Supplement 1): 386.

https://doi.org/10.1182/blood-2021-148210

Published: 2021

Journal Articles

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Blood (2021) 138 (Supplement 1): 139.

https://doi.org/10.1182/blood-2021-148682

Published: 2021

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Matthew J. Wieduwilt, MD PhD, Jan Cerny, MD PhD, Luke Akard, MD, Celalettin Ustun, MD, Farhad Ravandi, MD, James M. Rossetti, DO, Brian T. Hill, MD PhD, Janice (Wes) Brown, MD, Lois Kellerman, Rod Van Syoc, William Reed, MD, Charalambos Andreadis, MD MSCE

Blood (2014) 124 (21): 2268.

https://doi.org/10.1182/blood.V124.21.2268.2268

Published: 2014

Journal Articles

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Guillermo Garcia Manero, MD, Luger Selina, MD, Klimek Virginia, MD, Cooper Maureen, MD, Emmanuel C. Besa, MD, James M. Rossetti, DO, Richard Chao, MD, Rachel Humphrey, Lewis R. Silverman, MD

Blood (2013) 122 (21): 1550.

https://doi.org/10.1182/blood.V122.21.1550.1550

Published: 2013

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Heather L. Benjamin, MD, James M. Rossetti, DO, Aaron J. Lampkin, MSIV, Christie Hilton, DO, Entezam Sahovic, MD, Haifaa Abdulhaq, Richard K. Shadduck, MD, Namratha Vemulapalli, MD, Amanda Hercules, MD, John Lister, MD

Blood (2009) 114 (22): 4164.

https://doi.org/10.1182/blood.V114.22.4164.4164

Published: 2009

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia

George Labban, M.D., James M. Rossetti, D.O., Richard K. Shadduck, M.D., Entezam Sahovic, M.D., Haifaa Abdulhaq, M.D., Jean Goy, RN, Lisa Wilt, RN, Rich Wonder, RN, John Lister, M.D

Blood (2008) 112 (11): 4041.

https://doi.org/10.1182/blood.V112.11.4041.4041

Published: 2008

Journal Articles

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Haifaa Abdulhaq, MD, Bushra Haq, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, Entezam Sahovic, MD, Dijana Christianson, DO, John Lister, MD

Blood (2008) 112 (11): 5072.

https://doi.org/10.1182/blood.V112.11.5072.5072

Published: 2008

Journal Articles

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Casey A. Moffa, DO, Chandana Thatikonda, MBBS, Neeta Pathe, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4722.

https://doi.org/10.1182/blood.V110.11.4722.4722

Published: 2007

Journal Articles

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

James M. Rossetti, DO, Richard K. Shadduck, MD, Chandana Thatikonda, MBBS, Entezam Sahovic, MD, John Lister, MD

Blood (2007) 110 (11): 5034.

https://doi.org/10.1182/blood.V110.11.5034.5034

Published: 2007

Journal Articles

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

Chandanda Thatikonda, MBBS, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4387.

https://doi.org/10.1182/blood.V110.11.4387.4387

Published: 2007

Journal Articles

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

James M. Rossetti, DO, Eric Falke, Richard K. Shadduck, MD, Joan M. Latsko, MSN, CRNP, AOCNP, Wendy Kramer, John Lister, MD

Blood (2006) 108 (11): 4868.

https://doi.org/10.1182/blood.V108.11.4868.4868

Published: 2006

NARROW

An Analysis of Ruxolitinib Dosing for Myelofibrosis in Real-World Practice

A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)

A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only